ANSWER AND REASONINGC. Continue protocolled surveillance after checking measurement comparability and patient priorities
A single very small apparent change may reflect technique or measurement variability; management should integrate reproducible growth, symptoms, hearing and preferences.
Why every option is right or wrong
A. Immediate translabyrinthine excision: This sacrifices residual hearing and is disproportionate without confirmed progression or another compelling indication.
B. Stereotactic radiotherapy solely because any growth is seen: Treatment should not be triggered by an unverified millimetric difference alone.
C. Continue protocolled surveillance after checking measurement comparability and patient priorities: A single very small apparent change may reflect technique or measurement variability; management should integrate reproducible growth, symptoms, hearing and preferences.
D. Discharge from follow-up: A known tumour requires longitudinal surveillance even when initially stable.
E. Annual CT instead of MRI: CT is inferior for serial soft-tissue assessment and adds ionising radiation.
What if the scenario changed?
If serial comparable scans showed sustained growth with declining hearing, active treatment discussion would become more appropriate.